메뉴 건너뛰기




Volumn 115, Issue 14, 2010, Pages 2864-2871

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD20 ANTIBODY; HYBRID PROTEIN; RITUXIMAB;

EID: 77951019547     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-250555     Document Type: Article
Times cited : (93)

References (50)
  • 4
    • 0642312825 scopus 로고    scopus 로고
    • Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance
    • Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-7368.
    • (2003) Oncogene , vol.22 , Issue.47 , pp. 7359-7368
    • Smith, M.R.1
  • 5
    • 27244440161 scopus 로고    scopus 로고
    • Immunotherapy for non-Hodgkin's lymphoma: Monoclonal antibodies and vaccines
    • DOI 10.1200/JCO.2005.06.004
    • Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23(26):6421-6428. (Pubitemid 46218853)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.26 , pp. 6421-6428
    • Maloney, D.G.1
  • 6
    • 7244248664 scopus 로고    scopus 로고
    • From the bench to the bedside: Ways to improve rituximab efficacy
    • DOI 10.1182/blood-2004-03-1110
    • Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
    • (2004) Blood , vol.104 , Issue.9 , pp. 2635-2642
    • Cartron, G.1    Watier, H.2    Golay, J.3    Solal-Celigny, P.4
  • 7
    • 65549085367 scopus 로고    scopus 로고
    • Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" of rituximab
    • Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809-3812.
    • (2009) Blood , vol.113 , Issue.16 , pp. 3809-3812
    • Hilchey, S.P.1    Hyrien, O.2    Mosmann, T.R.3
  • 8
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammarIIIa gene
    • DOI 10.1182/blood.V99.3.754
    • Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
    • (2002) Blood , vol.99 , Issue.3 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6    Watier, H.7
  • 9
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • DOI 10.1200/JCO.2003.05.013
    • Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.21 , pp. 3940-3947
    • Weng, W.-K.1    Levy, R.2
  • 11
    • 0036090166 scopus 로고    scopus 로고
    • Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    • Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99(1):67-74.
    • (2002) Blood , vol.99 , Issue.1 , pp. 67-74
    • Ansell, S.M.1    Witzig, T.E.2    Kurtin, P.J.3
  • 12
    • 45749104147 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: Results of a phase II study
    • Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008;26(16):2725-2731.
    • (2008) J Clin Oncol , vol.26 , Issue.16 , pp. 2725-2731
    • Cartron, G.1    Zhao-Yang, L.2    Baudard, M.3
  • 13
    • 0036554140 scopus 로고    scopus 로고
    • Interferonalpha as an immunotherapeutic protein
    • Brassard DL, Grace MJ, Bordens RW. Interferonalpha as an immunotherapeutic protein. J Leukoc Biol. 2002;71(4):565-581.
    • (2002) J Leukoc Biol , vol.71 , Issue.4 , pp. 565-581
    • Brassard, D.L.1    Grace, M.J.2    Bordens, R.W.3
  • 16
    • 0034536334 scopus 로고    scopus 로고
    • Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells
    • DOI 10.1089/107999000750053799
    • Yanase N, Ohshima K, Ikegami H, Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Baxalpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 2000;20(12):1121-1129. (Pubitemid 32015252)
    • (2000) Journal of Interferon and Cytokine Research , vol.20 , Issue.12 , pp. 1121-1129
    • Yanase, N.1    Ohshima, K.2    Ikegami, H.3    Mizuguchi, J.4
  • 18
    • 0025673975 scopus 로고
    • Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders
    • Heslop HE, Bianchi AC, Cordingley FT, et al. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990;172(6):1729-1734.
    • (1990) J Exp Med , vol.172 , Issue.6 , pp. 1729-1734
    • Heslop, H.E.1    Bianchi, A.C.2    Cordingley, F.T.3
  • 19
    • 0021933901 scopus 로고
    • Close link between reduction of c-myc expression by interferon and, G0/G1 arrest
    • Einat M, Resnitzky D, Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature. 1985;313(6003):597-600.
    • (1985) Nature , vol.313 , Issue.6003 , pp. 597-600
    • Einat, M.1    Resnitzky, D.2    Kimchi, A.3
  • 20
    • 0034672243 scopus 로고    scopus 로고
    • Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
    • Xu D, Erickson S, Szeps M, et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood. 2000;96(13):4313-4318.
    • (2000) Blood , vol.96 , Issue.13 , pp. 4313-4318
    • Xu, D.1    Erickson, S.2    Szeps, M.3
  • 21
    • 25844480780 scopus 로고    scopus 로고
    • Review: Milstein Award lecture: Interferons and cancer: Where from here?
    • Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J Interferon Cytokine Res. 2005;25(9):511-527.
    • (2005) J Interferon Cytokine Res , vol.25 , Issue.9 , pp. 511-527
    • Borden, E.C.1
  • 22
    • 0033995976 scopus 로고    scopus 로고
    • Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia
    • DOI 10.1016/S0145-2126(99)00206-4, PII S0145212699002064
    • Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther. 2000;6(2):81-87. (Pubitemid 30227241)
    • (2000) Leukemia Research , vol.24 , Issue.5 , pp. 411-415
    • Venugopal, P.1    Sivaraman, S.2    Huang, X.-K.3    Nayini, J.4    Gregory, S.A.5    Preisler, H.D.6
  • 23
    • 0031656896 scopus 로고    scopus 로고
    • Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
    • Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64(3):358-367. (Pubitemid 28409243)
    • (1998) Journal of Leukocyte Biology , vol.64 , Issue.3 , pp. 358-367
    • Paquette, R.L.1    Hsu, N.C.2    Kiertscher, S.M.3    Park, A.N.4    Tran, L.5    Roth, M.D.6    Glaspy, J.A.7
  • 24
    • 0021933051 scopus 로고
    • Human interferon alpha in malignant lymphoma and Hodgkin's disease: Results of the American Cancer Society trial
    • Horning SJ, Merigan TC, Krown SE, et al. Human interferon alpha in malignant lymphoma and Hodgkin's disease: results of the American Cancer Society trial. Cancer. 1985;56(6):1305-1310.
    • (1985) Cancer , vol.56 , Issue.6 , pp. 1305-1310
    • Horning, S.J.1    Merigan, T.C.2    Krown, S.E.3
  • 25
    • 0025937962 scopus 로고
    • Interferon alpha in lymphoma
    • Rohatiner AZ. Interferon alpha in lymphoma. Br J Haematol. 1991;79(suppl 1):26-29.
    • (1991) Br J Haematol , vol.79 , Issue.SUPPL. 1 , pp. 26-29
    • Rohatiner, A.Z.1
  • 27
    • 0033993704 scopus 로고    scopus 로고
    • Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma
    • DOI 10.1023/A:1008384506227
    • Armitage JO, Coiffier B. Activity of interferonalpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol. 2000;11(3):359-361. (Pubitemid 30214677)
    • (2000) Annals of Oncology , vol.11 , Issue.3 , pp. 359-361
    • Armitage, J.O.1    Coiffier, B.2
  • 29
    • 0033911321 scopus 로고    scopus 로고
    • Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
    • Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6(7):2644-2652.
    • (2000) Clin Cancer Res , vol.6 , Issue.7 , pp. 2644-2652
    • Davis, T.A.1    Maloney, D.G.2    Grillo-Lopez, A.J.3
  • 30
    • 38549100096 scopus 로고    scopus 로고
    • Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
    • DOI 10.1080/10428190701704647, PII 789687799
    • Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49(1):102-112. (Pubitemid 351146889)
    • (2008) Leukemia and Lymphoma , vol.49 , Issue.1 , pp. 102-112
    • Kimby, E.1    Jurlander, J.2    Geisler, C.3    Hagberg, H.4    Holte, H.5    Lehtinen, T.6    Ostenstad, B.7    Hansen, M.8    Osterborg, A.9    Linden, O.10    Sundstrom, C.11
  • 31
    • 0035134688 scopus 로고    scopus 로고
    • Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
    • DOI 10.1634/theoncologist.6-1-34
    • Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34-55. (Pubitemid 32155814)
    • (2001) Oncologist , vol.6 , Issue.1 , pp. 34-55
    • Jonasch, E.1    Haluska, F.G.2
  • 32
    • 0038485519 scopus 로고    scopus 로고
    • Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model
    • DOI 10.1038/sj.gt.3301949
    • Suzuki K, Aoki K, Ohnami S, et al. Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther. 2003;10(9):765-773. (Pubitemid 36621820)
    • (2003) Gene Therapy , vol.10 , Issue.9 , pp. 765-773
    • Suzuki, K.1    Aoki, K.2    Ohnami, S.3    Yoshida, K.4    Kazui, T.5    Kato, N.6    Inoue, K.7    Kohara, M.8    Yoshida, T.9
  • 33
    • 7044245847 scopus 로고    scopus 로고
    • Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas
    • Ross JJ, Tu KL, Damato BE. Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas. Am J Ophthalmol. 2004;138(4):672-673.
    • (2004) Am J Ophthalmol , vol.138 , Issue.4 , pp. 672-673
    • Ross, J.J.1    Tu, K.L.2    Damato, B.E.3
  • 35
    • 33747621382 scopus 로고    scopus 로고
    • Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma
    • DOI 10.1038/sj.cgt.7700942, PII 7700942
    • Brin E, Atencio I, Helmich BK, Maneval D, Laface D. Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma. Cancer Gene Ther. 2006;13(7):664-675. (Pubitemid 44264471)
    • (2006) Cancer Gene Therapy , vol.13 , Issue.7 , pp. 664-675
    • Brin, E.1    Atencio, I.2    Helmich, B.K.3    Maneval, D.4    Laface, D.5
  • 36
    • 52949148222 scopus 로고    scopus 로고
    • Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis
    • De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299-311.
    • (2008) Cancer Cell , vol.14 , Issue.4 , pp. 299-311
    • De Palma, M.1    Mazzieri, R.2    Politi, L.S.3
  • 38
    • 38449120108 scopus 로고    scopus 로고
    • Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities
    • Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol. 2007;179(10):6881-6888.
    • (2007) J Immunol , vol.179 , Issue.10 , pp. 6881-6888
    • Huang, T.H.1    Chintalacharuvu, K.R.2    Morrison, S.L.3
  • 39
    • 67651163872 scopus 로고    scopus 로고
    • Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma
    • Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32(6):622-631.
    • (2009) J Immunother , vol.32 , Issue.6 , pp. 622-631
    • Betting, D.J.1    Yamada, R.E.2    Kafi, K.3    Said, J.4    Van Rooijen, N.5    Timmerman, J.M.6
  • 40
    • 70349271119 scopus 로고    scopus 로고
    • Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach
    • Cho JS, Kim YC, Morrison SL. Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach. PLoS One. 2009;4(9):e7029.
    • (2009) PLoS One , vol.4 , Issue.9
    • Cho, J.S.1    Kim, Y.C.2    Morrison, S.L.3
  • 41
    • 69449105856 scopus 로고    scopus 로고
    • Recombinant anti-CD20 antibody fragments for smallanimal PET imaging of B-cell lymphomas
    • Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for smallanimal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50(9):1500-1508.
    • (2009) J Nucl Med , vol.50 , Issue.9 , pp. 1500-1508
    • Olafsen, T.1    Betting, D.2    Kenanova, V.E.3
  • 42
    • 33745912405 scopus 로고    scopus 로고
    • A time- And cost-efficient system for high-level protein production in mammalian cells
    • DOI 10.1107/S0907444906029799
    • Aricescu AR, Lu W, Jones EY. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006;62(pt 10):1243-1250. (Pubitemid 44526216)
    • (2006) Acta Crystallographica Section D: Biological Crystallography , vol.62 , Issue.10 , pp. 1243-1250
    • Aricescu, A.R.1    Lu, W.2    Jones, E.Y.3
  • 43
    • 0024354304 scopus 로고
    • Determination of subcutaneous tumor size in athymic (nude) mice
    • Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154.
    • (1989) Cancer Chemother Pharmacol , vol.24 , Issue.3 , pp. 148-154
    • Tomayko, M.M.1    Reynolds, C.P.2
  • 45
    • 0023035950 scopus 로고
    • Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma
    • Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC. Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. J Immunol. 1986;137(9):3019-3024. (Pubitemid 17177817)
    • (1986) Journal of Immunology , vol.137 , Issue.9 , pp. 3019-3024
    • Basham, T.Y.1    Kaminski, M.S.2    Kitamura, K.3
  • 46
    • 3042737572 scopus 로고    scopus 로고
    • A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma
    • Neeson P, Paterson Y. A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a pre-clinical murine model for human lymphoma. Cytometry A. 2004;60(1):8-20. (Pubitemid 38859197)
    • (2004) Cytometry Part a , vol.60 , Issue.1 , pp. 8-20
    • Neeson, P.1    Paterson, Y.2
  • 47
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908. (Pubitemid 30412866)
    • (2000) Blood , vol.95 , Issue.12 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3    Lazzari, M.4    Borleri, G.-M.5    Bernasconi, S.6    Tedesco, F.7    Rambaldi, A.8    Introna, M.9
  • 48
    • 0032030699 scopus 로고    scopus 로고
    • Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
    • Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652. (Pubitemid 28110329)
    • (1998) Blood , vol.91 , Issue.5 , pp. 1644-1652
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 49
    • 70449729725 scopus 로고    scopus 로고
    • CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas
    • Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-{alpha}, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009;114(18):3864-3871.
    • (2009) Blood , vol.114 , Issue.18 , pp. 3864-3871
    • Rossi, E.A.1    Goldenberg, D.M.2    Cardillo, T.M.3    Stein, R.4    Chang, C.H.5
  • 50
    • 33847014608 scopus 로고    scopus 로고
    • Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
    • DOI 10.1158/0008-5472.CAN-06-2184
    • Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007;67(3):1270-1281. (Pubitemid 46270787)
    • (2007) Cancer Research , vol.67 , Issue.3 , pp. 1270-1281
    • Jazirehi, A.R.1    Vega, M.I.2    Bonavida, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.